Biogen’s $41‑plus‑CVR Deal Turns Apellis CFO’s Equity Into Cash and Future Payouts
Details on how Apellis shareholders received cash and CVRs in the Biogen buyout, and what it means for the CFO’s equity.
Apellis CFO equity awards reshaped in Biogen buyout
TL;DR
Biogen’s acquisition of Apellis gave shareholders $41 in cash plus a contingent value right that could add up to $4 more if milestones are hit. The deal turned Apellis CFO Timothy Sullivan’s equity awards into immediate cash and future milestone‑based payouts, while options priced at $45 or above were cancelled for no payment.
Context
Apellis Pharmaceuticals agreed to be bought by Biogen in March 2026, with the tender offer closing in May. Shareholders who tendered before the deadline received the cash‑and‑CVR package. The transaction made Apellis a wholly owned subsidiary of Biogen.
As part of the merger, all outstanding Apellis equity awards were re‑priced. Restricted stock units were converted into the same cash‑and‑CVR rights and continue to vest over time. Stock options were treated differently depending on their exercise price.
The chief financial officer, Timothy Sullivan, held a mix of RSUs, stock options, and common shares. His awards followed the same conversion rules applied to all employees and directors.
Key Facts
Each tendered share yielded $41.00 in cash and one contingent value right (CVR). A CVR is a contractual promise that can pay up to $4.00 in cash if certain development or regulatory milestones are met after the merger.
Stock options with an exercise price of $45.00 or higher were cancelled and received no consideration in the deal. Options below that threshold were exchanged for cash and/or CVRs based on their intrinsic value.
What It Means
For Sullivan, the cash portion provides immediate liquidity, while the CVRs give him a stake in future milestone payments tied to Apellis’s pipeline. The value of those CVRs will depend on whether Biogen achieves the agreed‑upon goals.
Options priced at $45 or above delivered no payout, highlighting how the merger’s terms punished deep‑out‑of‑the‑money awards. This outcome may affect retention and motivation of employees holding high‑strike options.
Investors should watch whether the milestones tied to the CVRs are met, as that will determine the additional cash flow to former shareholders, including the CFO. The next milestone review is expected later this year.
Continue reading
More in this thread
Conversation
Reader notes
Loading comments...